Your browser doesn't support javascript.
loading
NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential.
Miyazaki, Takahiro; Choi, Irene Y; Rubas, Werner; Anand, Neel K; Ali, Cherie; Evans, Juli; Gursahani, Hema; Hennessy, Marlene; Kim, Grace; McWeeney, Daniel; Pfeiffer, Juergen; Quach, Phi; Gauvin, David; Riley, Timothy A; Riggs, Jennifer A; Gogas, Kathleen; Zalevsky, Jonathan; Doberstein, Stephen K.
Afiliação
  • Miyazaki T; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Choi IY; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Rubas W; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Anand NK; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Ali C; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Evans J; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Gursahani H; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Hennessy M; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Kim G; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • McWeeney D; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Pfeiffer J; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Quach P; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Gauvin D; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Riley TA; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Riggs JA; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Gogas K; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Zalevsky J; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.).
  • Doberstein SK; Nektar Therapeutics, San Francisco, California (T.M., I.Y.C., W.R., N.K.A., C.A., J.E., H.G., M.H., G.K., D.M., J.P., P.Q., T.A.R., J.A.R., K.G., J.Z., S.K.D.); and MPI Research, Mattawan, Michigan (D.G.) sdoberstein@nektar.com.
J Pharmacol Exp Ther ; 363(1): 104-113, 2017 10.
Article em En | MEDLINE | ID: mdl-28778859
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Relacionados ao Uso de Substâncias / Analgésicos Opioides / Morfinanos Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: J Pharmacol Exp Ther Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Relacionados ao Uso de Substâncias / Analgésicos Opioides / Morfinanos Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: J Pharmacol Exp Ther Ano de publicação: 2017 Tipo de documento: Article